Print this page
-
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2
Expression
Protocol: 072305Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Pancreas -
Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial.
Protocol: 072306Principal Investigator:
- Brett Ecker MD (Rutgers Cancer Institute of New Jersey-University Hospital)
Applicable Disease Sites: Other Digestive Organ -
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
Protocol: 072108Principal Investigator:
- Russell Langan MD (Cooperman Barnabas, Livingston)
Applicable Disease Sites: Pancreas -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
A Phase II Study of Preoperative Pembrolizumab for Mismatch Repair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab.
Protocol: 071702Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Stomach -
A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.
Protocol: 071807Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon